Genprex Inc (GNPX)
2.44
+0.08
(+3.39%)
USD |
NASDAQ |
May 03, 16:00
2.34
-0.10
(-4.10%)
After-Hours: 20:00
Genprex Cash from Financing (TTM): 10.59M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 10.59M |
September 30, 2023 | 10.60M |
June 30, 2023 | 4.087M |
March 31, 2023 | 4.087M |
December 31, 2022 | 0.0064M |
September 30, 2022 | 0.0018M |
June 30, 2022 | 0.2435M |
March 31, 2022 | 0.3536M |
December 31, 2021 | 25.68M |
September 30, 2021 | 38.17M |
June 30, 2021 | 38.72M |
March 31, 2021 | 41.18M |
December 31, 2020 | 41.59M |
September 30, 2020 | 30.36M |
June 30, 2020 | 29.57M |
Date | Value |
---|---|
March 31, 2020 | 27.00M |
December 31, 2019 | 1.267M |
September 30, 2019 | 0.4168M |
June 30, 2019 | 0.2021M |
March 31, 2019 | 15.31M |
December 31, 2018 | 15.39M |
September 30, 2018 | 14.97M |
June 30, 2018 | 15.75M |
March 31, 2018 | 0.8714M |
December 31, 2017 | 0.794M |
September 30, 2017 | 2.294M |
June 30, 2017 | 2.890M |
March 31, 2017 | 2.706M |
December 31, 2016 | 2.706M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.0018M
Minimum
Sep 2022
41.59M
Maximum
Dec 2020
16.01M
Average
10.59M
Median
Dec 2023
Cash from Financing (TTM) Benchmarks
Lifecore Biomedical Inc | 56.06M |
Jaguar Health Inc | 34.23M |
BioXcel Therapeutics Inc | 26.52M |
TFF Pharmaceuticals Inc | 5.013M |
4D Molecular Therapeutics Inc | 156.83M |